The Maryland-based biotech Novavax has announced its COVID-19 vaccine candidate has 96.4% efficacy against COVID-19 illness from the original strain, sliding to 86.3% against the U.K. variant and falling to 48.6% in South Africa amid circulation of another concerning coronavirus variant.
